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The study determined the prevalence of MetS in patients with schizophrenia at the Psychiatric Unit of the Komfo Anokye Teaching
Hospital (KATH), Kumasi, Ghana. This comparative cross-sectional study recruited 348 schizophrenic patients comprising 236
antipsychotic-treated and 112 newly diagnosed treatment-naı¨ve patients. The MetS prevalence was assessed based on World
Health Organization (WHO), International Diabetes Federation (IDF), and the National Cholesterol Education Programme, Adult
Treatment Panel III (NCEP ATP III) criteria. The overall prevalence of MetS was 14.1%, 20.4%, and 23.6% using NCEP ATP III,
WHO, and IDF criteria, respectively, compared to 7.8%, 3.9%, and 2.2% reported in the generalGhanaian population.Theprevalence
was significantly higher among treated psychiatric patients compared to treatment-naı¨ve group based on NCEP ATP III (17.8%
versus 6.2%; p = 0.0001), WHO (26.2% versus 8.0%; p < 0.0001), and IDF (30.3% versus 10.0%; p < 0.0001). MetS was prevalent
among patients on atypical antipsychotics compared to typical antipsychotics irrespective of the criteria used (i.e., 17.1% versus
11.1% for NCEP ATP III; 29.5% versus 25.9% for WHO; and 44.3% versus 18.5% for IDF). Using logistic regression model, obesity,
raised fasting blood sugar, raised total cholesterol, and decreased high density lipoprotein were observed to be significant predictors
of MetS (p<0.05).The study found high prevalence of MetS in Ghanaians with schizophrenia and higher prevalence rate of MetS
associated with monotherapy. Regular monitoring of cardiometabolic parameters should be an important therapeutic objective in
the management of these patients.
1. Introduction
Schizophrenia is a chronic mental disorder which involves
disturbances of thought, perception, affect, and social behav-
ior [1]. It is ranked among the top ten causes of disability
worldwide with mortality rates two times as high as in the
general population [2–4]. Although accidents and suicide
account for just a portion of this high mortality rate, more
than two-thirds of the rate is caused by different forms
of comorbid physical diseases such as cardiovascular and
metabolic syndrome [3]. The emergence of these physical
diseases has been linked to poor lifestyle (smoking, sedentary
lifestyle, and poor diet) and cardiovascular risk factors
[5].
Metabolic syndrome (MetS) is a group of disorders
which includes central obesity, dyslipidemia, hypertension,
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abnormal glucose homeostasis, proinflammatory state, and
prothrombotic state [6, 7]. The prevalence of MetS seems to
be common and rising in the general population possibly
due to high intake of calories and a lifestyle of inactiv-
ity, irrespective of definition criteria [8, 9]. It is, however,
worth considering that some population groups and, for
that matter, particular patient groups even have an increased
propensity of developing MetS. Several studies have con-
vincingly indicated that schizophrenic patients are twice at
risk of developing MetS compared to the general popula-
tion [8, 10, 11]. Before the introduction of antipsychotics,
there were increasing reports of glucose dysregulations (i.e.,
glucose intolerance, insulin resistance, and hyperglycaemia)
by researchers in schizophrenic patients [12]. Moreover,
several recent studies have reported increased prevalence
of hyperglycaemia, insulin resistance, and impaired fast-
ing glucose tolerance in first episode, antipsychotic-na¨ıve
schizophrenic patients compared to healthy control subjects
[11].
Consequently, treatment with antipsychotics in people
with schizophrenia tends to worsen or even exacerbate these
MetS and, thus, contribute to the increased prevalence from
40% to 60% versus 30% in the general population [13, 14].
The atypical antipsychotics are generally known to possess
greater propensity of causing these metabolic abnormalities
than the typical antipsychotics. Concerning the metabolic
dysregulation that accompanied treatmentwith antipsychotic
medications, several studies have recommended a baseline
and continuous monitoring (every 6 months) of fasting
blood glucose, glycated haemoglobin, and fasting lipid profile
to be done in routine clinical practice with all atypical
antipsychotics [15–17].
However, in resource constraint health systems as we
find in psychiatric hospitals in Ghana, such monitoring is
not routinely undertaken, hence the difficulty in determining
the prevalence of these metabolic dysregulations. There is a
need for current data to serve as a basis for decision-making
in terms of routine monitoring for metabolic dysregulations
among these patients by healthcare providers in Ghana.
Therefore, this study sought to determine the prevalence of
MetS among patients with schizophrenia.
2. Methods
2.1. Study Design and Setting. This was a comparative cross-
sectional study which took place at the Out-Patient Depart-
ment of the Psychiatry Unit of Komfo Anokye Teaching
Hospital, (KATH) over a period of five (5) months (April to
August 2016). KATH is a 1200-bed facility located in Kumasi
in the Ashanti region of Ghana with a projected population
of 4,780,380 according to the 2010 census, accounting for
19.4% of Ghana’s total population. The Ashanti region is
centrally located in the middle belt of Ghana. It lies between
longitudes 0.15W and 2.25W, and latitudes 5.50N and 7.46N.
The region is divided into 27 districts. The Psychiatry Unit,
which is a department under Internal Medicine Directorate,
serves both in- and out-patients. About 150 schizophrenic
patients are attended to every month on out-patient basis at
the Psychiatry Unit.
2.2. Study Population and Subject Selection. This study com-
prised 112 newly diagnosed antipsychotic-na¨ıve and 236
patients on antipsychotics who were receiving treatment
at the psychiatric unit. These participants were randomly
selected into the study. Laboratory investigations which
include fasting blood glucose and lipid levels [triglycerides
(TG), low density lipoprotein (LDL), very low density
lipoprotein (VLDL), and total cholesterol (TC) as well as
measurements of blood pressure and anthropometric mea-
surements (height, weight, waist, and hip circumference)]
were carried out.
2.3. Inclusion Criteria. Patients with confirmed diagnosis of
schizophrenia according to the International Classification
of Diseases (ICD-10) criteria and attending the clinic for
review as scheduled by their medical doctors, who were
on either monotherapy or dual therapy (fluphenazine-based
combination therapies) of antipsychotics, and aged 18 years
and above were recruited randomly for the study.
2.4. Exclusion Criteria. In-patients and patients with known
history of diabetes or hypertension and who were on mood
stabilizers and antidepressants/benzodiazepines at the time of
enrollment in the study were excluded from the study.
2.5. Biochemical Analysis. About 5ml of venous blood sample
was collected after an overnight fast (12–16 hours) and
dispensed into fluoride oxalate tubes and vacutainer plain
tubes for separation into plasma and serum, respectively.
In the laboratory, the samples were centrifuged at 4000
revolution/minute for 5 min within 30 min of collection and
stored at -80∘C. Assay parameters included fasting plasma
glucose (FPG), triglycerides (TG), total cholesterol (TC),
low density lipoprotein (LDL), and high density lipoprotein
(HDL) cholesterol using the COBAS INTEGRA(R) 400 plus
automated chemistry analyzer.
2.6. Anthropometric Measurement. Anthropometric mea-
surements including height (measured without shoes) and
weight (to nearest 0.1 kg in light clothing) were taken.
Calculation of the Body Mass Indices (BMI) was done by
dividing weight (kg) by height squared (m2). With respect to
the BMI, there were four groupings of subjects: underweight
(BMI < 19 Kg/m2), normal (BMI between 19 and 24.9
Kg/m2), overweight (BMI between 25 and 29.9 Kg/m2), and
obese (BMI > or = 30 Kg/m2). The waist circumference (in
centimeter) was measured midway between the lowest rib
and the above iliac crest using the Gulick II spring-loaded
measuring tape (Gay Mill, WI). The hip circumference was
also measured (in centimeters) as the widest circumference
around the buttocks.The waist and hip circumference as well
as other parameters were used for the calculation of waist
to hip ratio (WHR), body adiposity (BAI) [18], and visceral
adiposity indices (VAI) [19].
2.7. Blood Pressure Measurement. Blood pressure (BP) was
recorded after 5 minutes of rest with the subject being in
the seated position using manual and an automated sphyg-
momanometer placed on the subject’s right arm. This was
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measured three times, and the average reading was recorded.
Individuals were deemed hypertensive if one ormore of these
features occur: they were taking antihypertensive medica-
tions, they self-reported a diagnosis of hypertension, systolic
pressure reading was above 140 mmHg, or diastolic pressure
reading was above 90 mm Hg.
2.8. Definition of Metabolic Syndromes. The three most com-
monly used definitions ofmetabolic syndrome, as used in this
study, are described below.
2.9. World Health Organization (WHO) Criteria. The WHO
criteria involve the presence of diabetes mellitus, insulin
resistance, or impaired glucose tolerance and any two of
the following: (1) body mass index (BMI) ≥ 30 kg /m2
and/or waist: hip ratio > 0.85 (female), > 0.90 (male); (2)
blood pressure, systolic ≥ 140 or diastolic ≥ 90 mmHg or on
medication; (3) triglyceride ≥ 1.7 mmol/L and/or HDL-C <
1.01 mmol/L (female), < 0.91 mmol/L (male) [20].
2.10. National Cholesterol Education Program, Adult Treat-
ment Panel III (NCEP ATPP III) Criteria. According to the
NCEP ATP III, individuals with metabolic syndrome should
have at least three of the following: (1) abdominal obesity
(waist circumference > 88 cm for women or > 102 cm for
men); (2) raised triglyceride (≥ 1.7 mmol/L); (3) low HDL
cholesterol (< 1.0 mmol/L in women or < 0.9 mmol/L in
men); (4) high blood pressure (systolic BP ≥ 130 mmHg or
diastolic BP ≥ 85 mmHg or treatment of hypertension); and
(5) raised fasting glucose (≥ 6.1 mmol/L) [21].
2.11. International Diabetes Federation (IDF) Criteria.
According to the IDF criteria, metabolic syndrome is
diagnosed if there is central obesity (waist > 80 cm for
women or circumference > 90 cm for men) in addition to
any two (2) of the following four (4) factors: (1) triglyceride
level ≥ 1.7 mmol/L; (2) HDL cholesterol < 1.29 mmol/L
for women or < 1.03 mmol/L for men; (3) blood pressure
≥ 130 /85 mmHg or treatment of previously diagnosed
hypertension; and (4) fasting blood glucose (FBG) ≥ 5.6
mmol/L or previously diagnosed type 2 diabetes [20].
2.12. Ethical Consideration. The investigationswere approved
by the Committee on Human Research Publications and
Ethics (CHRPE) at School of Medical Sciences, KNUST,
Ghana, and the Psychiatry Unit of KATH. Written informed
consent was obtained for all participants to maintain their
right to self- determination from their visitors/relatives.
2.13. Data Analysis. The data obtained were analyzed using
Statistical Package for Social Sciences SPSS (version 23.0),
statistical packages for Windows. Descriptive statistics that
were computed included frequencies and percentages for
all categorical variables in addition to means, standard
deviations, and ranges for all normally distributed continuous
variables, while median and interquartile range were used for
continuous variables that were not normally distributed. Dif-
ferences between groups were carried out using independent
sample t-test for continuous variable while Chi-square test
was used for categorical variables. Univariate binary logistic
regression model was used to detect factors associated with
MetS among schizophrenia patients. Statistical significance
was determined as p value <0.05.
3. Results
Subjects in the treatment group were slightly older (with
median age of 36 years) than the treatment-na¨ıve group
(median age = 32.5 years) but the difference was not sig-
nificant (p=0.2222). Majority of the study participants were
unemployed (55.5%), were single (58.9%), completed Junior
High School (45.3%), and had no family history of psychiatric
illness (69.1%). Also, several of the study subjects had no
history of alcohol intake and smoking (79.1%). Within the
antipsychotic-treated group, about half of these subjects
(51.3%) had been on a particular medication continuously for
more than 12 months [Table 1].
As shown in Table 2, prevalence of MetS was significantly
prevalent in subjects on antipsychotic treatment compared
to the treatment-na¨ıve patients for all the classifications
(p<0.05). Based on the NCEP/ATP III criteria, 17.8% of the
patients on treatment had MetS (score ≥3) compared to
6.2% of the treatment-na¨ıve patients with an odd ratio of
11.3 (p=0.0001). Using the IDF criteria, 30.3% of patients on
treatment compared to 9.8% of antipsychotic-na¨ıve patients
had developed MetS (OR = 12.6, p<0.0001). Similarly, the
WHO criteria revealed that 26.2% of the treated patients in
comparison with 8.0% of newly diagnosed patients hadMetS
with an odd ratio of 15.5 (p<0.0001).
The prevalence of MetS was higher in subjects on atypical
antipsychotics as compared to those on typical medications
for all the classifications, though no significant difference
was observed (p>0.05). Furthermore, the risk of developing
MetS increased with increasing score of MetS for the all
classifications (p>0.05).
It was observed that the odds of MetS increase steadily
with increasing bioscore of MetS for the individual classifi-
cations. Also, the prevalence of MetS was generally higher
in patients on the monotherapy than in those on the dual
therapy in all the classifications. There was, however, no
statistical difference observed (p>0.05). With respect to the
NCEP/ATP III criteria, there were increasing reduced odds of
MetS observed with patients on dual therapy with reference
to those on monotherapy (OR=0.6). However, no statistical
significant difference was observed (p=0.643). Similar obser-
vations were seen with the IDF and WHO criteria [Table 4].
Using NCEP/ATP III criteria as dependent variable,
obesity-WHR, obesity-WHtR, raised fasting blood sugar,
raised TC, raised triglycerides, and decreased HDL were
significantly associated with increased risks of MetS based
on logistic regression model. When the IDF criteria were
used as a dependent outcome, age range 50-59 years, obesity-
BMI, obesity-WHR, obesity-WHtR, raised FPG, raised TC,
raised TG, and raised LDL-C were significant predictors of
MetS. Using the WHO criteria as dependent variables, age
range 40-49 years, age≥60 years, obesity-BMI, obesity-WHR,
raised TG, and reducedHDL-Cwere statistically significantly
associated with increased risk of MetS [S1 and S2].
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Table 1: Sociodemographic characteristics of study participants.
Sociodemographics Psychotic-treated Treatment-naı¨ve 𝜒2,df p-value
n=236 n=112
Age (years) 36.0 (27.0 -45.0) 32.5 (24.8 - 45.3) 0.222
Age groups (years) 6.5,3 0.091
< 40 143(60.6) 76(67.9)
40 – 49 61(25.9) 16(14.3)
50 – 59 20(8.5) 11(9.2)
≥ 60 12(5.1) 9(8.0)
Gender 0.647
Male 115(48.7) 58(52.0)
Female 121(51.3) 54(48.0)
Marital status 10.4,3 0.015
Single 139(58.9) 56(50.0)
Married 79(33.5) 47(4.0)
Divorced 14(5.9) 2(1.8)
Widowed 4(1.7) 7(6.2)
Employment status 0.60,2 0.740
Unemployment 131(55.5) 65(58.0)
Employment 99(41.9) 43(38.3)
Student 6(2.5) 4(3.6)
Educational level 10.0,4 0.040
Primary 12(5.1) 11(9.8)
JHS 107(45.3) 56(50.0)
SHS 59(25.0) 18(16.1)
Tertiary 50(21.2) 18(16.1)
None 8(3.4) 9(8.0)
Family history of Psychotic illness 0.206
Yes 73(30.9) 27(24.1)
No 163(69.1) 85(75.9)
History of alcohol and smoking 3.2,3 0.365
Alcohol 20(8.5) 9(8.0)
Smoking 6(2.5) 0(0.0)
Alcohol and smoking 22(9.3) 9(8.0)
None 188(79.7) 94(84.0)
Duration of Treatment
< 3 months 23(9.8)
3 -8 months 44(18.6)
9 – 12 months 48(20.3)
>12 months 121(51.3)
df: degree of freedom; 𝜒2: chi-square; n: frequency; JHS: Junior High School; SHS: Senior High School; EPS: extrapyramidal symptoms; p<0.05 is statistically
significant.
4. Discussion
The prevalence of MetS seems to be common and rising in
the general population possibly due to high intake of calories
and a lifestyle of inactivity, irrespective of definition criteria
[9, 10]. Similar observationwasmadewhen the overall preva-
lence of MetS in this study was compared to the prevalence
rate reported from previous study in the general Ghanaian
population. Thus, the overall prevalence of MetS among
schizophrenic patients in Ghana as determined by IDF
(23.6%), WHO (20.4%), and NCEP ATP III (14.1%) in this
study was higher compared to the general Ghanaian popula-
tion prevalence rate (IDF = 7.8%, NCEP ATP III = 3.9% and
WHO = 2.2%) as determined by Owiredu et al. [22]. More-
over, a comparison of the overall prevalence from this study
to that obtained among psychiatric patients in Ghana shows a
consistent rise in the prevalence ofMetS among these patients
over the years regardless of definition criteria (IDF = 23.6%
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Table 2: MetS among psychotic-treated and treatment-na¨ıve studied subjects.
Variables Total Psychotic-treated Treatment-naı¨ve
n=348 n=236 n=112 cOR (95% CI) p-value
Met / NCEP/ATP III
0 75(21.6) 26(11.0) 49(43.8) 1
1 136(39.1) 93(39.4) 43(38.4) 4.1(2.2-7.4) 0.0013
2 88(25.2) 75(31.8) 13(11.6) 10.9(5.1-23.2) <0.0001
≥3 49(14.1) 42(17.8) 7(6.2) 11.3(4.5-47.6) 0.0001
Met / IDF
0 47(13.5) 16(6.7) 31(27.7) 1
1 123(35.3) 71(30.3) 52(46.4) 2.7(1.3 -5.3) 0.006
2 96(27.6) 78(32.7) 18(16.1) 8.4(3.8-18.5) <0.0001
≥3 82(23.6) 71(30.3) 11(9.8) 12.5(5.2-30.0) <0.0001
Met / WHO
0 65(18.7) 20(8.5) 45(40.2) 1
1 122(35.1) 75(31.8) 47(42.0) 3.6(1.9-6.8) <0.0001
2 90(25.9) 79(33.5) 11(9.8) 16.2(7.1-36.8) <0.0001
≥3 71(20.4) 62(26.2) 9(8.0) 15.5(6.5-37.2) <0.0001
NCEP ATP III: National Cholesterol Education Program, Adult Treatment Panel III; IDF: International Diabetes Federation; WHO: World Health
Organization; MetS: metabolic syndrome; cOR: crude odds ratio; CI: confidence interval.
versus 15.5%; WHO = 20.4% versus 13.5%; NCEP ATP
III = 14.1% versus 11.5%) [22, 23]. Furthermore, the MetS
prevalence observed in this study was in agreement with a
range of prior reports published regionally and worldwide,
although there is a considerable variation in criteria and
methodology among the published reports [13, 16, 24–26].
However, studies about prevalence rate of MetS are very
few in Africa, with most of the studies originating from the
southern and northern part of Africa [16, 27–31].
Moreover, the prevalence ofMetSwas significantly higher
among schizophrenic patients on antipsychotic treatment
than the treatment-naı¨ve group, which concurs with findings
from Saddichha et al. [11] who reported a high prevalence
of MetS among antipsychotic-treated group compared with
matched healthy control group. Findings from Grover et al.
[32]and Shakeri et al. [33] also reported similar findings
that MetS was highly prevalent among patients treated with
antipsychotics, hence increasing their risk of developing
cardiovascular diseases. The smaller prevalence observed
in the newly diagnosed treatment-naı¨ve group from the
current study further implies that exposure to antipsychotics
contributes largely, but not singularly, to the development of
cardiometabolic disorders among schizophrenics as well as
mentally ill patients.
Among the antipsychotic medications, numerous stud-
ies have indicated higher prevalence of MetS associated
with atypical antipsychotic use as compared to the typical
medications [5, 34]. This is not consistent with the present
study; though the current study showed a higher prevalence
of MetS in patients on atypical antipsychotics for all the
classification criteria compared to the typical drugs, no
statistical significant difference was observed [Table 3]. The
higher metabolicogenic ability of atypical antipsychotics may
be due to their affinity for a wide range of receptor systems
(serotonergic, adrenergic, cholinergic, and histaminergic
receptors) other than the traditional dopaminergic activity
[5]. Several reports have also shown that some atypical
antipsychotics have greater propensity of causing metabolic
syndrome compared to othermedicines within the same class
[35–37]. Furthermore, studies by Shirzadi and Ghaemi and
Lieberman reported that clozapine and olanzapine treated
subjects were at increased risk of weight gain, dyslipidaemias,
and hyperglycaemia when compared with other atypical
antipsychotics as well as typicalmedicines. [15, 37].Therefore,
these reports have provided undeniable evidence of the
metabolicogenic ability of olanzapine as well as clozapine and
permit the inclusion of a black-box warning in prescriptions
of these medicines. It is, however, worth noting that strict
monitoring of metabolic parameters is paramount for all
schizophrenic patients irrespective of antipsychotic used.
Currently, antipsychotic polypharmacy is commonly seen
in clinical practice for the management of schizophrenia in
most countries as well as Ghana [38]. This practice is not
explicitly recommended in most clinical practice guidelines
exemplified by National Institute for Health and Care Excel-
lence (NICE), Ghana Standard Treatment Guidelines 2010,
and World Federation of Societies of Biological Psychiatry
[39]. However, most clinicians use combination therapies in
treatment resistant cases or when unsatisfactory response
to standard dose of monotherapy is observed [38]. In spite
of this, studies that compare the efficacy of mono- and
combination therapies have been inconclusive [38]. Further-
more, several cross-sectional studies have reported increased
prevalence of metabolic effects and cardiovascular mortality
associated with antipsychotic cotreatment [40, 41]. Contrary
to these findings, the present study revealed a higher preva-
lence of MetS associated with monotherapy. Since this study
did not consider simultaneous initiation of cotreatment at the
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Table 3: MetS among studied subjects treated with atypical and typical antipsychotics.
Variables Total Atypical Typical
n=159 n=105 n=54 OR (95% CI) p-value
Met / NCEP/ATP III
0 12(7.5) 6(5.7) 6(11.1) 1
1 65(41.3) 41(39.1) 24(44.5) 1.7(0.5-5.9) 0.522
2 58(36.2) 40(38.1) 18(33.3) 2.2(0.6-7.8) 0.316
≥3 24(15.0) 18(17.1) 6(11.1) 3.0(0.6-12.9) 0.157
Met / IDF
0 8(5.0) 4(3.8) 4(7.4) 1
1 50(31.5) 26(24.8) 24(44.5) 1.1(0.1-9.0) 1.000
2 56(35.2) 44(41.9) 12(22.2) 3.7(0.8-16.9) 0.099
≥3 45(28.3) 31(29.5) 14(25.9) 2.2(0.5-10.2) 0.421
Met / WHO
0 12(7.6) 6(5.7) 6(11.1) 1
1 53(33.3) 34(32.0) 19(35.2) 1.8(0.5-6.3) 0.512
2 55(34.6) 36(34.0) 19(35.2) 1.9(0.5-6.7) 0.341
≥3 39(24.5) 29(44.3) 10(18.5) 2.9(0.8-11.1) 0.157
NCEP ATP III: National Cholesterol Education Program, Adult Treatment Panel III; IDF: International Diabetes Federation; WHO: World Health
Organization; MetS: metabolic syndrome; OR: odds ratio; CI: confidence interval; p<0.05 is statistically significant.
Table 4: MetS among studied subjects on dual and mono antipsychotic therapy.
Variables Total Dual therapy Monotherapy OR (95% CI) p-value
n=236 n=77 n=159
Met / NCEP/ATP III
0 26(10.9) 14(18.1) 12(7.5) 1
1 93(39.5) 27(35.1) 66(41.5) 0.4(0.1-0.9) 0.034
2 75(31.9) 18(23.4) 57(38.9) 0.3(0.1-0.7) 0.007
≥3 42(17.7) 18(23.4) 24(15.1) 0.6(0.2-1.7) 0.643
Met / IDF
0 16(6.7) 8(10.4) 8(5.0) 1
1 71(30.3) 22(28.6) 49(30.8) 0.5(0.2-1.4) 0.159
2 78(32.7) 22(28.6) 56(35.2) 0.4(0.1-1.12) 0.138
≥3 71(30.3) 25(32.4) 46(28.9) 0.6(0.2-1.6) 0.393
Met / WHO
0 10(8.4) 8(10.4) 12(7.5) 1
1 38(31.9) 22(28.6) 54(33.9) 0.6(0.2-1.7) 0.418
2 40(33.6) 24(31.2) 55(34.6) 0.7(0.2-1.8) 0.431
≥3 31(26.1) 24(31.2) 38(23.9) 0.9(0.3-2.7) 1.000
NCEP ATP III: National Cholesterol Education Program, Adult Treatment Panel III; IDF: International Diabetes Federation; WHO: World Health
Organization; MetS: metabolic syndrome; OR: odds ratio; CI: confidence interval.
beginning of the data collection, it is possible that the adverse
effects observed may be related to the direct effect of specific
antipsychotic rather than the combination therapy.
Nevertheless, it is unclear whether reports from those
previous studies are related to cohort effect, as patients who
were selected for antipsychotic combination therapy were
psychiatrically and physically sicker than those onmonother-
apy. Also, such studies mostly considered clozapine- based
therapies rather than fluphenazine-based combination ther-
apy as used in this present study [42]. Moreover, this
finding could also be explained by the fact that there are
more rapid metabolizers in treatment resistant patients.
Thus they might experience fewer side effects. Also they
might smoke more or use more cannabis, both affecting
metabolic syndrome rates. Consequently, it is difficult to
assume such risks for all other combination therapies. It
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is therefore important that longer-term studies of sufficient
methodological quality and sample size be conducted to
provide sufficient evidence to support the efficacy, long-
term safety, mortality, and cost of antipsychotic cotreat-
ment.
The association between age and development of MetS
has been widely reported. The prevalence of MetS increases
with age in the general population and a similar trend
had been generally observed in patients with schizophrenia
[17, 33]. Conversely, some studies have also revealed a peak
of MetS rates in the third, fourth, or fifth decade of life
with subsequent decline in MetS rates in later life [26, 43].
The present study revealed significantly increased risk of
MetS in both younger (<49 years) and older (>50 years)
age groups as defined by the IDF and WHO classifications.
Furthermore, a critical assessment of the significant odds
of developing MetS per the IDF and WHO classifications
showed that the risk of MetS increased exponentially with
increasing age. The increased risk of MetS observed in
the younger age group may be attributed to the fact that
patients within this group may have a greater predisposition
to developing MetS despite being exposed to antipsychotics.
Thus, the exposure to antipsychotics may be thought of as
quickening MetS onset instead of precipitating it de novo.
Also, the significant risk observed in the older ages suggests
that, in those groups, age may be a more important risk
factor for comorbid MetS as against the neuroleptic pre-
scribed.
From the study, the prevalence of MetS was found to be
higher in female subjects compared to the male counterparts
but was not statistically significant according to the NCEP
ATP III criteria. However, significantly higher prevalence
rate was observed in the IDF and WHO classifications. Also,
females were approximately 3-4 times at risk of developing
MetS compared to the males. These findings agree with a
study by You-Kyung et al., [44] who found a significantly
higher prevalence rate ofMetS in female subjects compared to
males according to the IDF classification. However, Sugawara
et al. [45] together with other fewer studies [13, 46] have
reported slightly higher MetS prevalence rate in men or
no significant differences in MetS rates across sexes. The
higher prevalence of MetS in females may be attributed to a
more sedentary lifestyle, obesity, and age-related physical and
hormonal changes [47].
Several studies have suggested that schizophrenia is an
independent risk factor for diabetes due to disease-related
stress and poor lifestyle of patients [3, 48]. Also, studies
have shown that exposure to antipsychotics further predis-
poses patients to hyperglycaemia, new onset diabetes, and
diabetic ketoacidosis in schizophrenic patients with higher
risk associated with atypical antipsychotics than the typi-
cal medicines [49–51]. Logistic regression model indicates
that hyperglycaemia (FPG > 6.4 mmol/L) was significantly
associated with higher risks of MetS among patients treated
with antipsychotics according to the IDF criteria [Table
6]. These findings concur with previous studies that have
identified high prevalence of hyperglycemia and risk of
MetS in patients on antipsychotics [49, 52]. Weight gain
may be the most obvious signal of MetS and is usually the
most distressing issue among patients, thus contributing to
noncompliance to antipsychotic medications [53]. Increased
abdominal adiposity as measured by waist circumference is
important causative risk factor for MetS and a prerequisite
for the diagnosis of MetS by the IDF criteria. Results from
the logistic regression in this study showed that obesity as
defined by BMI, WHR, andWHtR as per the NCEP ATP III,
WHO, and IDF criteria were significant predictors of MetS.
This shows that both atypical and typical antipsychotics have
an almost equal propensity in inducing central obesity (i.e.,
per definition using WHR) in patients on medication. This
is in accordance with reports by Allison et al. and Bobes
et al.[14, 54] which revealed that typical antipsychotics and,
to a greater extent, atypical medicines are associated with
metabolic disturbances and weight gain.
Dyslipidaemia is an important component of the meta-
bolic syndrome and occurs along with glucose dysregulation
andweight gain in patients treatedwith antipsychotics. Logis-
tic regression model revealed that dyslipidaemia (defined
as increased TC, TG, and LDL as well as reduced HDL-
C) in patients on antipsychotic treatments was associated
with increased risk of MetS in all the classifications, though
not statistically significant. This agrees with a study by
Owiredu et al. [22] which showed that hypertriglyceridaemia
and reduced HDL cholesterol were significant risk factors
for metabolic syndrome associated with antipsychotic use,
especially atypical medicines. In a study to explore the associ-
ation between hyperglycaemia and antipsychotic use, Haupt
and Newcomer [55] suggested that dyslipidaemia as well
as increased abdominal obesity impairs glucose metabolism
leading to treatment-related hyperglycaemia and type 2
diabetes mellitus. This could therefore explain the significant
finding of diabetes observed in patients on antipsychotics
treatments in this study.
Notwithstanding, findings in this study are comparable
to reports from numerous studies. The study faced some
limitations that may affect the generalizability of the results.
First, as the study subjects were patients at a single psychiatric
hospital, the results obtained from their examination cannot
be generalized for the entire population of schizophrenic
patients in Ghana. Secondly, variables that can impact MetS,
such as physical condition, diet, severity of symptoms, dura-
tion of illness, physical activity level, and socioeconomic
status, were not adequately evaluated.
5. Conclusion
The prevalence of MetS among the psychotic-treated patients
in this study is triple that previously reported in nonpsychotic
individuals.MetSwas also prevalent among patients on atypi-
cal and monotherapy than those on typical and dual antipsy-
chotic medications. Regular monitoring of cardiometabolic
parameters should be an important therapeutic objective in
the management of these patients.
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